Exbivirumab: Difference between revisions

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

@@ Line 1: / Line 1: @@
+{{Short description|Monoclonal antibody}}
 {{Drugbox
 | Verifiedfields = changed
-| verifiedrevid = 448027381
+| verifiedrevid = 457121609
+<!-- Monoclonal antibody data -->
-<!--Monoclonal antibody data-->
 | type = mab
 | mab_type = mab
 | source = u
 | target = [[hepatitis B]] surface antigen
+<!-- Clinical data -->
-<!--Clinical data-->
 | tradename =
 | pregnancy_AU =
@@ Line 20: / Line 19: @@
 | legal_status =
 | routes_of_administration =
+<!-- Pharmacokinetic data -->
-<!--Pharmacokinetic data-->
 | bioavailability =
 | protein_bound =
@@ Line 27: / Line 25: @@
 | elimination_half-life =
 | excretion =
+<!-- Identifiers -->
+| CAS_number_Ref = {{cascite|changed|??}}
-<!--Identifiers-->
+| CAS_number = 569658-80-6
-| CAS_number_Ref = {{cascite|correct|??}}
+| UNII_Ref = {{fdacite|correct|FDA}}
-| CAS_number = <!-- blanked - oldvalue: 569658-80-6 -->
+| UNII = 5Q374M1S1P
 | ATC_prefix = none
 | ATC_suffix =
@@ Line 37: / Line 36: @@
 | DrugBank =
 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-| ChemSpiderID = NA
+| ChemSpiderID = none
+<!-- Chemical data -->
+| C=6416 | H=9924 | N=1732 | O=1982 | S=44
-<!--Chemical data-->
-| C=6416 | H=9924 | N=1732 | O=1982 | S=44
 | molecular_weight =
 }}
-'''Exbivirumab''' is a [[human]] [[monoclonal antibody]]<ref>[http://whqlibdoc.who.int/druginfo/INN_2005_list53.pdf WHO Drug Information]</ref> developed for the treatment of [[hepatitis B]] infections.<ref>{{cite journal|last=Shouval|first=D|coauthors=et al.|year=2006|title=Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatits B Virus (Hbv) in Liver Transplant (Lt) Recipients|journal=Hepatology|volume=44|issue=4|doi=10.1002/hep.21395 | page=196A|pmid=17001593|pages=188A–700A}}</ref>
+'''Exbivirumab''' is a [[human]] [[monoclonal antibody]]<ref>{{Cite web |url=http://whqlibdoc.who.int/druginfo/INN_2005_list53.pdf |title=WHO Drug Information |access-date=2009-09-24 |archive-url=https://web.archive.org/web/20110511203141/http://whqlibdoc.who.int/druginfo/INN_2005_list53.pdf |archive-date=2011-05-11 |url-status=dead }}</ref> developed for the treatment of [[hepatitis B]] infections.<ref>{{cite journal| vauthors = Shouval D, Terrault N, Galun E, Samuel D, Gane E, Pruett T, Rustgi V, Shrestha R, Mukherjee S, Stravitz R, Reddy R | display-authors = 6 |year=2006|title=Anti-Viral Effects, Pharmacokinetics and Safety of Two Human Monoclonal Anti-Hbs (Libivirumab/Exbivirumab) Versus Hepatitis B Immune Globulin (Hbig) in Hepatitis B Virus (Hbv) in Liver Transplant (Lt) Recipients|journal=Hepatology|volume=44|issue=4|doi=10.1002/hep.21395 |pages=188A–700A [196A] |doi-access=free}}</ref>
 ==References==
@@ Line 51: / Line 49: @@
 {{Monoclonals for infectious disease and toxins}}
+[[Category:Experimental monoclonal antibodies]]
 {{antiinfective-drug-stub}}
 {{monoclonal-antibody-stub}}
-[[it:Exbivirumab]]